HOME >> MEDICINE >> NEWS
NIAID scientists unveil mechanism behind resistance to severe malaria

Scientists have discovered why people with a specific type of hemoglobin--the oxygen-carrying molecule that gives red blood cells their color--are less prone to severe malaria. In a series of experiments, the researchers determined how hemoglobin type C impairs the ability of malaria parasites to cause disease symptoms.

"This research gives us a new insight into malaria, a major global killer that preys especially on young children and claims a life every 30 seconds," notes Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, where the research was conducted.

"If we better understand the natural protective mechanisms against malaria, we might be able to mimic that protective effect through vaccines or drugs," says NIAID researcher Thomas E. Wellems, M.D., Ph.D., whose team's findings appear this week in the journal Nature.

Hemoglobin exists in several varieties. Hemoglobin A is the most common, but in parts of West Africa, where malaria is rife, one-fourth of the population has at least one gene for hemoglobin C. Children with at least one hemoglobin C gene are less prone to deadly cerebral malaria, in which parasite-infected red blood cells accumulate in the brain. But how hemoglobin C confers this protection has puzzled scientists until now.

To solve the mystery, Dr. Wellems and his colleagues studied laboratory-infected red blood cells and blood drawn from children with malaria from the African nation of Mali. Genetically, the samples fell into three groups: those with two genes for hemoglobin A (AA); those with two genes for hemoglobin C (CC); or those with one gene for each type of hemoglobin (AC).

The scientists then measured three phenomena that affect how well parasitized red blood cells can be made to stick to one another, to uninfected red blood cells and to blood vessel walls. These phenomena--known respectively as aggl
'"/>

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
22-Jun-2005


Page: 1 2

Related medicine news :

1. NIAID releases MDR/XDR Tuberculosis research agenda
2. NIAID DNA vaccine for H5N1 avian influenza enters human trial
3. NIAID media availability: Examining genetic variability of malaria parasite offers insight
4. NIAID awards $4 million to develop anti-radiation treatments
5. Partnership between NIAID and Sequella yields promising new TB drug for clinical testing
6. NIAID announces leadership for newly restructured HIV/AIDS clinical trials networks
7. NIAID study finds higher dose of flu vaccine improves immune response in the elderly
8. NIAID media availability: New study describes key protein from highly pathogenic H5N1 avian flu virus and how it might mutate
9. NIAID media availability: Understanding influenza infection
10. NIAID researchers show how promising TB drug works
11. NIAID awards $47 million to develop medical countermeasures against radiological, nuclear threats

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/20/2017)... ... September 20, 2017 , ... Medicare ... at risk of price gouging for their prescription drugs, according to a new ... Medicare isn’t negotiating on our behalf, there’s no consistency in drug pricing among ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Finn Mouseson”: follows the ... in an average life. This mouse sets out on a journey that will show ... Mouseson” is the creation of newly published author and illustrator, Melody Gersonde-Mickelson, who has ...
(Date:9/20/2017)... , ... September 20, 2017 , ... “The Financial Favor ... “The Financial Favor of God; Second Edition” is the creation of published author, Brooks ... take this opportunity to talk to you about the financial favor of God. Not ...
(Date:9/19/2017)... York, NY (PRWEB) , ... September 19, 2017 ... ... firm, announced today the addition of strategic marketing leader, Denise Flannery, to its ... Strategic Marketing, Brand and Management Consultant, Denise will work with clients across different ...
(Date:9/19/2017)... Dallas, TX (PRWEB) , ... September 19, 2017 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – will return to Texas as a part of its national Swirl: ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)...  Eli Lilly and Company (NYSE: ... to more efficiently focus resources on developing new ... workforce reductions, including those from a U.S. voluntary ... 3,500 positions. With the streamlining ... approximately $500 million that will begin to be ...
(Date:9/7/2017)... , Sept. 7, 2017 Caris Life ... on fulfilling the promise of precision medicine, today ... the benefits of its molecular profiling approach in ... comprehensive genomic profiling plus (CGP+) with Caris Molecular ... tumor on a molecular level, leading to more ...
(Date:9/7/2017)... , Sept. 7, 2017  Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced that it will be participating ... Healthcare Conference at the Grand Hyatt hotel in New ... 2017 at 11:40 a.m. Eastern Time. A ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
Breaking Medicine Technology:
Cached News: